뉴스벤징가
Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study
· 발표
기사 요약
Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…